BioInvent International AB (publ) EBIT

The latest EBIT for BOVNF is $-500M as of June 2026. That compares with $-320M in the prior-year period — down 55.4% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside BioInvent International AB (publ)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, BOVNF's EBIT moved from $-320M to $-500M — a 55.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in BioInvent International AB (publ)'s operating scale or balance-sheet position.

Against Healthcare companies, BOVNF currently prints $-500M for EBIT, while the sector average sits near $110B. That is roughly 100.5% below the sector mean. Large gaps often invite a closer look at BioInvent International AB (publ)'s growth, margins, and balance sheet.

A EBIT figure of $-500M for BOVNF is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting BOVNF's EBIT ($-500M), review year-over-year change from $-320M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.